ClinicalTrials.gg
RecruitingNCT06541990HARMONYUpdated Oct 9, 2026

Psychoeducational Intervention for Patients With Hepatocellular Carcinoma

An interventional study of HARMONY and Enhanced usual care in Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital — 3 open to participants now, 5 under way, none of them phase 3. Carcinoma, Hepatocellular · Massachusetts General Hospital.

Planned enrollment
Largest of 12
50 · median 29
Started
2024
the only one that year
No phase
2 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital, this one has the largest planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 2 with no phase, and was the 14th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

3 of the 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).

Read the detailed description

There are two parts of this study. Study Part 1 is an open pilot study to refine HARMONY prior to larger-scale testing in a randomized controlled trial (RCT) setting. Study Part 1 is purely descriptive, as the investigators will use the data to refine HARMONY before proceeding to Study Part 2.

Study Part 2 is a pilot RCT to assess the feasibility and acceptability of conducting a randomized trial of HARMONY versus enhanced usual care. Participants will complete a baseline survey and then be randomized to HARMONY versus enhanced usual care (a supportive care resource guide). This record reflects the clinical trial component (Study Part 2), as feasibility and acceptability outcomes will be collected for this phase only.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • New diagnosis of HCC within the last six months
  • Ability to complete study procedures English

Exclusion criteria

Exclusion Criteria:

  • Incidentally diagnosed with HCC after liver transplantation
  • Significant uncontrolled hepatic encephalopathy, cognitive impairment, or psychiatric disorder which will interfere with study participation
  • Patients near the end of life for whom hospice is recommended
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HARMONY

    HARMONY is a psychoeducational intervention that consists of three one-on-one coaching sessions and a structured session workbook.

    Behavioral: HARMONY

  • Active comparator
    Enhanced usual care

    The enhanced usual care condition consists of a curated list of supportive care services for patients with HCC.

    Other: Enhanced usual care

Interventions

  • BehavioralHARMONY

    A psychoeducational intervention for patients with HCC

  • OtherEnhanced usual care

    A supportive care resource guide

06

What researchers measure

Primary outcomes

  1. Feasibility: study enrollment rate

    ≥40% enrollment among consecutive eligible patients

    Time frame: 10 weeks

Secondary outcomes

  1. Feasibility: intervention completion rate

    ≥50% completion of 2/3 intervention sessions in the HARMONY arm

    Time frame: 10 weeks

  2. Acceptability

    ≥70% of patients in the HARMONY arm reporting Client Satisfaction Questionnaire-8 (CSQ-8) scores at or above the midpoint score of 20 on a scale from 8-32

    Time frame: 10 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 29 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Jun 2026 → Mar 2027 and completion Sep 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2024
First posted
Aug 7, 2024
StartActual
Oct 28, 2024
Primary completionEst.
Mar 31, 2027was Jun 2026
CompletionEst.
Jun 30, 2027was Sep 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Mar 31, 2027
Oct 9, 2026
Study completion
Sep 30, 2026→Jun 30, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Jun 30, 2026→Mar 31, 2027
    Study completion Sep 30, 2026→Jun 30, 2027
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06541990
Responsible party
Kelsey S. Lau-Min, MD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Aug 7, 2024
Start date
Oct 28, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Kelsey Lau-Min
Contact
klau-min@mgh.harvard.edu
617-724-4000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion